BIOMAT Database Logo BIOMAT Database Logo

Response to publications by Heyward W et al. and Kuan R et al.: Clinical and cost-effectiveness analyses, respectively, of hepatitis B vaccination-Heplisav™ compared with Engerix-B(®) vaccine in adults. 2015

Marc De Ridder, and Desmond Curran, and Geert Leroux-Roels
GlaxoSmithKline Vaccines, Belgium; Faculté de Pharmacie, Université Libre de Bruxelles, Belgium. Electronic address: marc.r.de-ridder@gsk.com.

UI MeSH Term Description Entries
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D017325 Hepatitis B Vaccines Vaccines or candidate vaccines containing inactivated hepatitis B or some of its component antigens and designed to prevent hepatitis B. Some vaccines may be recombinantly produced. Hepatitis B Vaccine,Vaccine, Hepatitis B,Vaccines, Hepatitis B

Related Publications

Marc De Ridder, and Desmond Curran, and Geert Leroux-Roels
Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine.
August 2013, Vaccine,
Marc De Ridder, and Desmond Curran, and Geert Leroux-Roels
Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney disease.
May 2023, Vaccine,
Marc De Ridder, and Desmond Curran, and Geert Leroux-Roels
Fendrix® Vaccine Effectiveness in Healthcare Workers Who Are Non-Responsive to Engerix B® Vaccination.
March 2021, Vaccines,
Marc De Ridder, and Desmond Curran, and Geert Leroux-Roels
Serological response with Heplisav-B® in prior Hepatitis B vaccine non-responders living with HIV.
October 2021, Vaccine,
Marc De Ridder, and Desmond Curran, and Geert Leroux-Roels
Cost-Effectiveness of an Adjuvanted Hepatitis B Vaccine (HEPLISAV-B) in Patients With Inflammatory Bowel Disease.
January 2021, Crohn's & colitis 360,
Marc De Ridder, and Desmond Curran, and Geert Leroux-Roels
Immunogenicity and safety of a booster dose of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) compared with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in adults receiving hemodialysis who previously received hepatitis B vaccination and are not seroprotected: Results of a randomized, multicenter phase 3 study.
November 2022, Human vaccines & immunotherapeutics,
Marc De Ridder, and Desmond Curran, and Geert Leroux-Roels
A real world comparison of HepB (Engerix-B®) and HepB-CpG (Heplisav-B®) vaccine seroprotection in patients receiving maintenance dialysis.
February 2023, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
Marc De Ridder, and Desmond Curran, and Geert Leroux-Roels
A randomized, controlled clinical trial to evaluate the immunogenicity of a PreS/S hepatitis B vaccine Sci-B-Vac™, as compared to Engerix B®, among vaccine naïve and vaccine non-responder dialysis patients.
February 2018, Clinical and experimental nephrology,
Marc De Ridder, and Desmond Curran, and Geert Leroux-Roels
Cost-effectiveness of adult pneumococcal vaccination: response to Grabenstein et al.
April 2013, Vaccine,
Marc De Ridder, and Desmond Curran, and Geert Leroux-Roels
Cost-effectiveness of hepatitis B vaccination in adults with diagnosed diabetes.
January 2013, Diabetes care,
Copied contents to your clipboard!